An off-label use with uneven evidence
Low-dose naltrexone (LDN)
LDN is naltrexone prescribed at a much lower dose than addiction-treatment tablets. It is discussed for pain, fibromyalgia, and several inflammatory conditions, but the quality and direction of evidence differ sharply by condition.
What is low-dose naltrexone (LDN)?
Low-dose naltrexone refers to naltrexone prescribed at doses typically between 0.5 mg and 6.0 mg per day — far below the standard 50 mg dose used for addiction treatment. The most commonly reported dose is 4.5 mg per day, usually taken at bedtime.
The theoretical basis for LDN is different from addiction treatment. At low doses, naltrexone is thought to:
- Briefly block opioid receptors, triggering a rebound increase in endogenous opioid production (endorphins and enkephalins)
- Modulate immune function through antagonism at Toll-like receptor 4 (TLR4) on microglial cells — a proposed anti-inflammatory mechanism
These are hypotheses. Human studies have not established one LDN mechanism that explains benefit across all of these conditions.
Low doses may require a pharmacy-prepared formulation where no suitable authorised strength is available. Do not improvise a liquid or divide a product unless a prescriber and pharmacist have confirmed the exact preparation and measurement.
The evidence by condition
A summary of clinical evidence for LDN across the most studied conditions, based on the 2026 systematic review of 105 studies.
Fibromyalgia
Most studied condition with 9 controlled trials (RCTs) enrolling approximately 430 participants at 4.5–6.0 mg/day. Early small trials (2013–2014) reported pain reductions of 30–60%. However, larger, more rigorous trials including the FINAL trial (2024, n=99, parallel-group, 6 mg/day) and a 2023 European crossover study (n=52, 4.5mg/day) found NO superiority of LDN over placebo for pain. A 2024 meta-analysis reported small but statistically significant pain reduction (MD: −0.86 on NRS), but clinical significance of this effect size is uncertain. A large INNOVA trial (n=120, 12-month follow-up) is in progress.
Chronic pain (other types)
LDN has been studied in painful diabetic neuropathy (comparable to amitriptyline but better tolerated), osteoarthritis and inflammatory arthritis (no significant benefit over placebo in controlled trials), HIV-associated pain (no superiority over gabapentin or placebo), and complex regional pain syndrome. Retrospective studies report improvements but lack control groups. A consistent pattern: open-label studies report benefit, placebo-controlled trials show modest or no effect.
Multiple sclerosis
Two placebo-controlled crossover RCTs (n=60 and n=96) at 4.5 mg/day. The smaller trial found improvements in mental health quality of life and pain but not fatigue or physical function. The larger trial found no consistent benefits across quality of life domains (MSQoL-54). Evidence is inconclusive and inconsistent.
Autoimmune and gastrointestinal
Small studies in inflammatory bowel disease (Crohn's, ulcerative colitis) show possible benefit but findings are inconsistent. Evidence for autoimmune conditions (lupus, rheumatoid arthritis) is predominantly from case reports and small uncontrolled series. No large-scale RCTs support routine use. Dermatological applications (psoriasis, eczema) are supported only by case reports.
Mental health and other
Studies in depression, PTSD, and post-infectious syndromes (including long COVID) are almost exclusively case reports and small uncontrolled series. The few placebo-controlled trials have not demonstrated clear clinical benefit. Oncological applications (cancer-related fatigue, tumour progression) are experimental with no controlled human evidence for efficacy.
What the data shows
Key statistics from the 2026 systematic review (Advances in Therapy).
- Total studies reviewed
- 105
- Most common dose
- 4.5 mg
- Randomised controlled trials
- 15
- Evidence conclusion
- Not routine
15 RCTs, the rest case reports, case series, and observational studies
Once daily, typically at bedtime. 0.5–6.0 mg range used across studies
Across 7 therapeutic areas. Most positive findings from smaller/earlier studies
Review states current evidence 'does not support routine clinical use'
Questions worth settling before an LDN trial
Does the evidence fit my exact condition?
Evidence quality differs sharply by condition. Ask about the best controlled trials for your diagnosis, not a combined success claim across unrelated illnesses.
Does ‘low dose’ mean low risk?
Not automatically. Short studies often report tolerability, but long-term evidence is thinner. Opioid interactions, other medicines, pregnancy, liver health, formulation quality, and the risk of delaying proven care still matter.
How would I obtain the exact dose?
Availability depends on local authorised products and pharmacy-compounding rules. Use a prescriber and licensed pharmacist; do not improvise a dilution or measurement from an online recipe.
Is the mechanism proven?
The proposed transient receptor blockade and immune effects are hypotheses. They have not been shown to explain benefit across all conditions grouped under the LDN label.
What if I use opioid pain medicine?
Tell the prescriber before considering LDN. Even a lower naltrexone dose can affect opioid response or create withdrawal risk. In an emergency, tell the treating team that you take naltrexone and let them manage pain using the current clinical protocol.
How will we know whether it worked?
Agree on one or two measurable symptoms, a review date, a meaningful-change threshold, and a stopping rule. Also decide what evidence-based care continues during the trial.
Make an LDN trial answerable
If a clinician suggests LDN, agree on the symptom being measured, the review date, what counts as meaningful improvement, and when to stop. That turns an open-ended experiment into a decision.
Sources
- Low-Dose Naltrexone: What is the Evidence? A Narrative Review
Reviews 105 studies, including 15 randomised controlled trials, and emphasises the limits of routine clinical use.
- Fibromyalgia LDN systematic review and meta-analysis of randomised trials
Controlled-trial synthesis used for the fibromyalgia evidence summary.
Content and sources reviewed